Abstract
AbstractPurpose The complement system plays an important role in the pathogenesis of Age‐related Macular Degeneration (AMD). In this study we examined the effect of lutein on circulating levels of Complement Factor D (CFD), a rate limiting component of the alternative pathway of complement activation.Methods Blood samples were collected from 82 early AMD patients from The Netherlands and the UK that took part in a one year multi centre, double masked, placebo controlled intervention trial with lutein supplementation. CFD was measured by ELISA.Results We found a significant 0.12 μg/ml monthly decrease in serum CFD concentration in the lutein group (p<0.001), resulting in a 61% decrease from 2.33 μg/ml at baseline to 0.91 μg/ml at 12 months. We found no change in the placebo group.Conclusion Lutein supplementation markedly decreases circulating CFD levels thereby offering a simple method to control the alternative complement pathway.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
